Trial Profile

A Prospective, Randomised Study to Assess Safety, Changes in Platelet Reactivity, Plasma Cardiac Biomarkers, Immunological and Metabolic Parameters in HIV-1 Infected Subjects Undergoing a Switch in Antiretroviral Therapy.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Maraviroc (Primary) ; Abacavir; Didanosine; Peptide hydrolase inhibitors
Indications HIV-1 infections
Focus Pharmacodynamics
Acronyms SMASH

10 Sep 2019 Status changed from completed to discontinued.
20 May 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 42% to 45%.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com